Cristcot

Cristcot

Private
Concord, MassachusettsHealthcare & Life Scienceshttps://www.cristcot.com

Last Round

Series B

Oct 23, 2019

Total Funding Raised

$13.73M

Company Overview

Cristcot is a healthcare company that develops a disposable suppository applicator designed for the hygienic administration of rectal medications to treat various conditions such as constipation, gastrointestinal diseases, and chronic pain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

ulcerative colitis treatmenthydrocortisone acetate suppositorysuppository applicatorgastrointestinal diseasesGI diseasesSephure applicatordrug delivery systemrescue therapyinflammatory bowel diseaseIBDclinical-stage pharmagastroenterologybiotechdrug formulationacute pancreatitishemorrhoid disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cristcot Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cristcot Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BOct 23, 2019

Key People

Founding team and executive leadership

CCRP Jennifer Davagian

President And CEO

Executive Team

C.G. Mark C. Ensign

Chief Operating Officer Chief Scientific Officer

Executive Team

Cristcot Investors

Notable investors and investment history

InvestorRounds
Shepherd Kaplan KrochukSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Preparing for commercial launch of novel ulcerative colitis treatment.

  • Aug 11, 2025

    First product, a therapy for ulcerative colitis, is in Phase 3 trials.

Cristcot Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cristcot Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cristcot's valuation, stock price, and market status.

Firmographic Details

HeadquartersConcord, Massachusetts
Employee Range31
Year Founded2008
Last FundingOct 23, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.